glucose fresenius kabi 10 %
fresenius kabi s.r.o., Česká republika - sacharidy - 76 - infundibilia
polyoxidonium 6 mg
medigroup s.r.o., slovensko - iné imunostimulanciá (zmena who) - 59 - immunopraeparata
formoterol-ratiopharm 12 µg
ratiopharm gmbh, nemecko - formoterol - 14 - bronchodilatantia, antiasthmatica
coffeinum bioveta 125 mg/ml injekčný roztok
bioveta, Česká republilka - inj.
hyaluronan bioveta 10 mg/ml
vetservis, slovenská republika - inj.
ventipulmin 0,016 mg/g granulát pre kone
boehringer ingelheim vetmedica, srn - gran.
vzduch medicinálny syntetický linde
linde gas a.s., Česká republika - medicinálny vzduch - 87 - varia i
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiká - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).